One Health between Humans and Animals
to provide a new solutions as vaccines and therapeutics for infectious or common diseases
between humans and animals.
News & Topics
Our Business
Synthetic Peptide Vaccines
Pan-Coronavirus Vaccine: CoV-mMAP
We are developing a pan-coronavirus vaccine (CoV-mMAP) that targets all coronaviruses including feline infectious peritonitis (FIP) and COVID-19. The pan-coronavirus vaccine is designed to be applicable for any kinds of mutated viruses and avoidable for antibody-dependent enhancement (ADE).
Antibody Drugs
Allergy Immunotherapeutics (for dogs): E-mab
We will develop an allergy immunotherapeutics (E-mab) which can directly eliminate IgE-producing B-cells. E-mab differentiates the closed (non-pathogenic) form of IgE from the open form (pathogenic) of IgE. Since the closed form exists on the cell surface of IgE-producing B-cells, E-mab can attack and eliminate them when utilized as an antibody drug without interfered by serum pathogenic IgE (open form) in allergy patients. Due to the selection of conserved region between IgEs of dogs and humans, E-mab is applicable for allergic diseases in both dogs and humans.
Technology Features
By accumulative achievement under the collaborative research with the Institute of Physical and Chemical Research (RIKEN) and the Animal Allergy Clinical Laboratories (AACL, Inc.) with addition of our original ideas combined with logical approach in biology, we will develop and contribute to revolutionary vaccines and therapeutics for both animals and humans in the fields of zoonosis and allergic disease.
Access
5-4-30 Nishihashimoto, Midori-ku, Sagamihara,
Kanagawa